In Parallel Mouse Studies, Researchers Fail to Replicate Many Reported Effects of Psilocybin
The consortium found psilocybin reliably triggered immediate fear suppression and head-twitch responses in mice, but no measurable behavioral benefits remained after 24 hours.
7 Articles
7 Articles
A study on silocybin, the active ingredient in "magic mushrooms" touted as a miracle cure for depression and PTSD, has been published that is likely to spark major debate in the medical world.
In parallel mouse studies, researchers fail to replicate many reported effects of psilocybin
Experimental trials of psychedelic drugs in both humans and animals have produced conflicting results, creating doubts about whether hallucinogens have a therapeutic role in treating neurologic or behavioral disorders such as depression and PTSD.
Psilocybin's lasting mood benefits fail a five-lab mouse test
A five-laboratory collaboration found that psilocybin acutely increased anxiety-like behavior and reduced fear expression in mice but produced no replicable persistent antidepressant-like, anxiolytic or fear-extinction effects 24 hours after a single dose.
Psilocybin, being studied as a potential treatment for depression, may produce less lasting behavioral changes than previous studies suggested. Five independent laboratories failed to confirm many of the reported effects, reports Nature Neuroscience.
Psilocybin, the active ingredient in magic mushrooms, does not make mice permanently less anxious or depressed. This is evident from an unusual experiment. Five labs conducted exactly the same experiment and combined their results. Many effects that previously appeared in separate studies did not hold up. Psychedelics are making a comeback in medicine. Small studies in humans suggest that […] More science? Read the latest articles on Scientias.n…
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
